T 0799/16 of 04.09.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T079916.20190904
- Date of decision
- 4 September 2019
- Case number
- T 0799/16
- Petition for review of
- -
- Application number
- 11160247.0
- IPC class
- A61K 31/44
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods of Using Sustained Release Aminopyridine Compositions
- Applicant name
- Acorda Therapeutics, Inc.
- Opponent name
- Actavis Group PTC ehf
Synthon B.V.
neuraxpharm Arzneimittel GmbH - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 123(3) (2007)European Patent Convention Art 54 (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 83 (2007)
- Keywords
- Amendments - allowable (yes)
Sufficiency of disclosure - (yes)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- T 1212/97
- Citing cases
- T 1045/21
Order
For these reasons it is decided that:
1. The decision under appeal is set aside
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the set of claims labelled "main request - August 2016" enclosed with the statement setting out the grounds of appeal and a description to be adapted thereto.